ReviewCureus2026
Epidermal Growth Factor Receptor (EGFR) Amplification and Survival in Patients With Glioblastoma: A Systematic Review and Meta-Analysis.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma has been described as the most common and aggressive primary brain neoplasm in adults, with limited survival despite multimodal therapy. The prognostic impact of epidermal growth factor receptor (EGFR) amplification and its interaction with isocitrate dehydrogenase (IDH) mutation and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation remains unclear. This systematic review and meta-analysis examined how EGFR amplification level and molecular profile affect overall survival (OS) in glioblastoma. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines, a systematic review was performed for studies reporting OS stratified by EGFR amplification, MGMT methylation, or IDH mutation. Using a random-effects model, pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated, and I² statistics were employed to assess heterogeneity. Nine studies including 1,766 subjects were analyzed. Low or moderate EGFR amplification showed no OS impact (HR=0.98 (95% CI: 0.88-1.09); HR=0.94 (95% CI: 0.81-1.10)), whereas high amplification predicted worse survival (HR=1.19; 95% CI: 1.14-1.24; p<0.00001). EGFR amplification with MGMT methylation correlated with poorer outcomes (HR=1.38; 95% CI: 1.33-1.44), while EGFR amplification with unmethylated MGMT showed improved survival (HR=0.68; 95% CI: 0.61-0.76). Stratification by IDH status identified EGFR-negative/IDH-mutant tumors as the most favorable group (HR=0.44; 95% CI: 0.29-0.67) and EGFR-positive/IDH-wildtype as the least favorable (HR=1.33; 95% CI: 0.89-2.00). High EGFR amplification independently predicts worse survival in glioblastoma, particularly with MGMT promoter methylation and IDH-wildtype status. Integrating EGFR, MGMT, and IDH profiles refines prognostic assessment and supports personalized therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.